• 1
    Davis BE,Herr HW,Fair WR,Bosl GJ. The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy. J Urol. 1994; 152: 111113.
  • 2
    Rabbani F,Farivar-Mohseni H,Leon A,Motzer RJ,Bosl GJ,Sheinfeld J. Clinical outcome after retroperitoneal lymphadenectomy of patients with pure testicular teratoma. Urology. 2003; 62: 10921096.
  • 3
    Saxman SB,Nichols CR,Foster RS,Messemer JE,Donohue JP,Einhorn LH. The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers. J Urol. 1996; 155: 587589.
  • 4
    National Comprehensive Cancer Network. Testicular Cancer. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, version 1, 2007. Available at URL: Accessed May 28, 2007.
  • 5
    Carver BS,Motzer RJ,Kondagunta GV,Sogani PG,Sheinfeld J. Late relapse of testicular germ cell tumors. Urol Oncol. 2005; 23: 441445.
  • 6
    Aass N,Klepp O,Cavallin-Stahl E, et al. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. J Clin Oncol. 1991; 9: 818826.
  • 7
    Fossa SD,Qvist H,Stenwig AE,Lien HH,Ous S,Giercksky KE. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J Clin Oncol. 1992; 10: 569573.
  • 8
    Steyerberg EW,Keizer HJ,Fossa SD, et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from 6 study groups. J Clin Oncol. 1995; 13: 11771187.
  • 9
    Toner GC,Panicek DM,Heelan RT, et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol. 1990; 8: 16831694.
  • 10
    Fossa SD,Ous S,Lien HH,Stenwig AE. Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. J Urol. 1989; 141: 557559.
  • 11
    Oldenburg J,Alfsen GC,Lien HH,Aass N,Waehre H,Fossa SD. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol. 2003; 21: 33103317.
  • 12
    Beck SD,Foster RS,Bihrle R, et al. Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in post-chemotherapy nonseminomatous testis cancer. J Urol. 2002; 168: 14021404.
  • 13
    Donohue JP,Rowland RG,Kopecky K, et al. Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J Urol. 1987; 137: 11761179.
  • 14
    [No authors listed.] International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers.International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997; 15: 594603.
  • 15
    Baniel J,Foster RS,Gonin R,Messemer JE,Donohue JP,Einhorn LH. Late relapse of testicular cancer. J Clin Oncol. 1995; 13: 1170116.
  • 16
    Baniel J,Foster RS,Einhorn LH,Donohue JP. Late relapse of clinical stage I testicular cancer. J Urol. 1995; 154: 13701372.
  • 17
    Carver BS,Bianco FJJr,Shayegan B, et al. Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection. J Urol. 2006; 176: 100103.
  • 18
    Motzer RJ,Amsterdam A,Prieto V, et al. Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. J Urol. 1998; 159: 133138.
  • 19
    Eggener SE,Carver BS,Sharp DS,Motzer RJ,Bosl GJ,Sheinfeld J. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. J Urol. 2007; 177: 937942.